Skip to main content
. 2013 Sep 30;8(9):e76025. doi: 10.1371/journal.pone.0076025

Figure 4. Edaravone protected MGO enhanced OGD-induced injury in the cultured HBMEC.

Figure 4

(A) HBMEC were incubated with MGO (2 mmol/l) for 24 h before 3 h OGD. Cell viability was determined by MTT assay. (B) HBMEC were incubated with edaravone (100 µmol/l), aminoguanidine (1 mmol/l) 20 min before MGO (2 mmol/l) treatment. After 24 h MGO treatment, the cultured HBMEC was incubated under OGD condition for another 3 h. Cell viability was determined by MTT assay. (C) Cell mortality was determined by LDH assay. (D, E, F) HBMEC were incubated with edaravone (100 µmol/l) 20 min before MGO (2 mmol/l) treatment. After 24 h MGO treatment, the cultured HBMEC was incubated under OGD condition for another 3 h. RAGE, AGEs were determined by Western blotting. $p<0.05 versus MGO group. *p<0.05 versus control group. #p<0.05 versus OGD group. &p<0.05 versus MGO+OGD group. n = 3 repeats. AG represented aminoguanidine. ED represented edaravone.